Biogen Product Services
Biogen provides and funds a range of services and offerings support the effective use of our MS treatments and support patient care.
Patient Support Programmes
Biogen’s patient support programmes are delivered by an independent third party nurse service provide educational information to patients with regards to their treatment. Support programmes are in place for Avonex® (interferon beta-1a), Plegridy® (peginterferon beta-1a), Tecfidera® (dimethyl fumarate) and Tysabri®▼ (natalizumab) (UK Only). Enrollment of a patient into a support programme can only occur after the prescribing decision has been made.
The Avonex and Plegridy Patient Support Programme provides at-home injection training and phone support to patients for their prescribed injectable therapy.
The Tecfidera Support Line is a nurse-led telephone line that provides patients prescribed Tecfidera with educational assistance and support.
The Tysabri Infusion Nurse Service is aimed at NHS HCPs to support patients prescribed Tysabri with the administration of Tysabri.
Biogen offers Clinical Homecare Services to MS patients who are being treated with Avonex, Plegridy, Fampyra and Tecfidera. This service enhances the overall healthcare service offering to patients including greater patient choice of care delivery at a time and place which is convenient to them; at home, work or at a UK holiday location. Proactive prescription management and regular contact with patients reduce risk of missed doses and improves adherence to treatment.
Biogen work closely with four homecare providers to offer choice of service provider and ensure high quality clinical homecare services which are secure, fully traceable with a temperature-assured supply chain with full UK coverage. Biogen invest dedicated resource to assure the quality of clinical homecare service provided and ensure the service continues to meet the needs of patients and healthcare professionals. The homecare providers include Alcura, Healthcare at Home, HealthNet and LLoydsPharmacy Clinical Homecare.
Motivational interviewing (MI) is a patient-centred, directive method for enhancing intrinsic motivation to change. It is a powerful tool for nurses to support behaviour change in patients.
Biogen is providing motivational interviewing skills training to MS and neurology nurses in the UK & Ireland. The learning objectives are for participants to:
Identify how MI can be used as a tool to support behaviour change in people with MS
Discover how to apply the principles of MI to improve the well-being of people with MS
- Describe the elements of four key MI techniques
- Gain direct experience of using an MI approach during skills-practice sessions
The programme has been developed in consultation with nurses and is designed to facilitate on- going, peer-to-peer support.
PML can be a risk factor with some DMTs and dealing with a suspected case in an MS patient can be a complicated and difficult process for Healthcare Professionals. To meet this need, Biogen has developed a comprehensive electronic resource pack which provides Healthcare Professionals with information that will help to assist with reporting, investigating and managing suspected case of PML. To receive a copy of a resource pack for the identification and management of suspected PML cases in patients treated with DMTs, speak to your local Biogen representative, or email using the button below, for more information.
Non-Medical Prescribing Educational Update Meeting
Annual CPD accreditid meeting providing essential clinical and medicolegal updates to support sumptomatic and desease modifying prescribing, with plenaries and interactive workshops. Specifically designed for non-medical prescribers in MS, e.g. specialist nurses or pharmacists with the non-medical prescribing qualification to prescribe.
SpR Training Day
An educational day that is delivered by neurologists on the latest developments in MS along with key topics associated to general neurology. Specifically designed for neurology trainees, this day will cover a wide range of disscusion points from diagnostic assessments to managment of disease relapse and safety vigilance.